- ≥99% by HPLC; lot-matched COA available
- Lot-matched certificate of analysis
- Ships next business day, tracked
Retatrutide
Triple GIP, GLP-1 and glucagon receptor agonist peptide, research grade
- FormLyophilized powder, sealed glass vial with flip-off seal
- Mol. weight4731.30 g/mol
- Research areasMulti-receptor metabolic signaling, energy expenditure, hepatic lipid handling
Supplied for laboratory research use only. Not for human or veterinary use, and not intended to diagnose, treat, cure or prevent any disease.
Overview
Retatrutide is a synthetic 39-residue peptide engineered to engage three metabolic receptors — GIP, GLP-1 and glucagon — from a single GIP-based backbone. Its design combines several stabilizing elements described in the medicinal-chemistry literature: alpha-aminoisobutyric acid residues that resist dipeptidyl peptidase-4 cleavage, an alpha-methyl-leucine substitution, and a lysine-linked AEEA/gamma-glutamyl spacer bearing a C20 fatty diacid for reversible albumin binding, with a C-terminal serinamide.
The triple-agonist concept is the reason laboratories want it. Adding glucagon receptor activity to incretin agonism introduces a potential energy-expenditure and hepatic-lipid component that neither GLP-1 nor dual GIP/GLP-1 agonists provide, and separating those contributions is an active research question. Groups use retatrutide to measure relative potency at each receptor, to test whether the three signals interact additively in cell and rodent systems, and as a comparator when new multi-agonist scaffolds are profiled.
Specifications
Identity
- CAS number
- 2381089-83-2
- Molecular formula
- C221H342N46O68
- Molecular weight
- 4731.30 g/mol
- Peptide class
- Acylated triple GIP/GLP-1/glucagon receptor agonist
Supply & purity
- Form
- Lyophilized powder, sealed glass vial with flip-off seal
- Purity
- ≥99% by HPLC; lot-matched COA available
- Available sizes
- 10 mg, 20 mg, 30 mg, 48 mg, 60 mg
- Solubility
- Bacteriostatic water; dilute alkaline or phosphate buffers also used
Handling & storage
- Storage (lyophilized)
- −20 °C, sealed and protected from light and moisture
- Storage (reconstituted)
- 2–8 °C, protected from light; use within the study window
Additional detail
- Backbone length
- 39 amino acids, GIP-based sequence
- Key modifications
- Aib residues, alpha-Me-Leu, Lys-linked (AEEA)-gamma-Glu-C20 diacid, C-terminal serinamide
- Research areas
- Multi-receptor metabolic signaling, energy expenditure, hepatic lipid handling
Questions about Retatrutide
How does retatrutide differ from tirzepatide?
Tirzepatide engages two incretin receptors, GIP and GLP-1. Retatrutide adds glucagon receptor activity, which is why laboratories study it when the research question involves energy expenditure or hepatic lipid handling rather than incretin signaling alone.
What purity and paperwork come with it?
Every lot is tested by HPLC to at least 99% purity with identity confirmed by mass spectrometry. A lot-matched certificate of analysis is available and corresponds to the exact vial number you receive, so assay data can be traced back to the material.
How should the vial be stored?
Keep the sealed lyophilized vial at −20 °C, protected from light and moisture. After reconstitution, store at 2–8 °C, protect from light and use within your documented study window. Aliquot to avoid repeated freeze-thaw cycles.
Is a full amino acid sequence provided?
Retatrutide is a 39-residue peptide with Aib substitutions, an alpha-methyl-leucine and a lysine-linked C20 diacid side chain. Because vendors differ in how they render modified residues, we point to the lot certificate of analysis for the definitive structural description.
Related
